+Search query
-Structure paper
Title | BRD810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models |
---|---|
Journal, issue, pages | to be published |
Publish date | Jun 15, 2023 (structure data deposition date) |
![]() | Rauh, U. / Wei, G. / Serrano-Wu, M. / Kosmidis, G. / Kaulfuss, S. / Siegel, F. / Thede, K. / McFarland, J. / Poncet-Montange, G. / Lemke, T.L. ...Rauh, U. / Wei, G. / Serrano-Wu, M. / Kosmidis, G. / Kaulfuss, S. / Siegel, F. / Thede, K. / McFarland, J. / Poncet-Montange, G. / Lemke, T.L. / Werbeck, N. / Nowak-Reppel, K. / Pilari, S. / Menz, S. / Ocker, M. / Kaushik, V. / Hubbard, B. / Ziegelbauer, K. / Golub, T.R. |
![]() | Search PubMed |
Methods | X-ray diffraction |
Resolution | 1.56 Å |
Structure data | ![]() PDB-8t6f: |
Chemicals | ![]() ChemComp-MG: ![]()
ChemComp-YI7: ![]() ChemComp-DMS: ![]() ChemComp-PGE: ![]() ChemComp-HOH: |
Source |
|
![]() | APOPTOSIS / Inhibitor / MCL1 / MBP-fusion / BRD810 |